Press Releases

The U.S. Food and Drug Administration has approved Jardiance® 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. Jardiance is not recommended in patients with type 1 diabetes. It may increase the risk of diabetic ketoacidosis in these patients. Jardiance is not recommended for use to improve glycemic control in patients with type 2 dia

CMP Pharma, Inc. announced today that Liqrev Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-made oral liquid of sildenafil, is now available. Liqrev is a liquid oral suspension of sildenafil formulated for patients with dysphagia or difficulty swallowing tablets. Liqrev is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. FDA-approved Liqrev addresses the inconsistencies that come from

Geron Corporation, a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). “This pioneering achievement t

Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on the statistically significant and clinically meaningful radiographic progression-free survival (rPFS) data from the P

MIMETAS, a global leader in human disease modeling announces that it has expanded its ongoing partnership with Astellas, a global pharmaceutical company, to include automation and application support. “We are truly honored by the trust of the Astellas team in our capabilities,” says Paul Vulto, CEO of MIMETAS. “Astellas is a true innovation leader that understands the importance of human-relevant tissue and disease modeling for novel therapy development. We will co

As part of its role as an enabler for research and innovation, Department of Health – Abu Dhabi, the regulator of the healthcare sector in the emirate, has honoured the winners of the inaugural Healthcare Innovation Bootcamp. The ceremony was held in presence of Her Excellency Dr Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. The inaugural four-day Healthcare Innovation Bootcamp challenge is the fruit of an ongoing collaboration between DoH and

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited , "Sun Pharma" is pleased to announce Health Canada’s approval of PrWINLEVI (clascoterone cream 1%). WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, and the newest Health Canada-approved formulation to target the hormonal component of acne for Canadian patients in 40 years.1

AntlerA Norrin/Wnt-agonist antibody through a strategic partnership with EyeBio enters clinical trials for treatment of retinopathies. AntlerA previously reported the development of a Norrin/Wnt-mimetic for treatment of leaky blood vessels in the eye. "We are pleased to support EyeBio in the development and advancement of EYE103, a Norrin/Wnt-mimetic, into the clinic. Built based on AntlerA’s ANT-Pharm platform the tetravalent antibody molecule binds specificall

PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets. The collaboration will leverage PrecisionLife’s proprietary combinatorial analytics platform to analyze patient genomic profiles an

SERDA therapeutics, a biopharmaceutical company, announces that it has submitted an Investigational New Drug Application (IND) to the US FDA today for its lead product SN514 hydrogel, an innovative enzymatic wound debriding agent. Clinical studies are expected to start in Q2 2023. SN514 hydrogel is a topical debridement product designed to remove eschar rapidly and effectively from severe burn wounds and chronic ulcers, including pressure injury ulcers, venous leg ulcers (open leg)